Stephen Kraus

Stephen Kraus, a partner in the Cambridge, Mass. office, has worked with Bessemer Venture Partners since 2004 and focuses on the healthcare sector. Mr. Kraus has been actively involved in Bessemer’s investments in Sirtris Pharmaceuticals (NASDAQ: SIRT, acquired by GlaxoSmithKline); Affymax (NASDAQ: AFFY); Aveo (NASDAQ: AVEO); Alnara, acquired by Eli Lilly; Transave (NASDAQ: INSM); Stromedix, acquired by Biogen Idec; Verastem (NASDAQ: VSTM); and Restore Medical (NASDAQ: REST, acquired by Medtronic). He currently sits on the boards of Verastem, Allena Pharmaceuticals, Alcresta, Liazon and OvaScience, and is actively involved in BVP’s investments in Acceleron and Proteon. Prior to joining Bessemer, Mr. Kraus was a director at the Ironwood Equity Fund, a growth-stage, private-equity firm, and a management consultant at Bain & Co. In 2002, he served as speechwriter and operations director for the Democratic nominee for governor of Massachusetts. Mr. Kraus graduated summa cum laude with a B.A. from Yale University and earned his M.B.A. from Harvard, where he was a Baker Scholar. He serves on the boards of the New England Venture Capital Association (NEVCA), the Achievement Network, and Interise.